BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. J Exp Clin Cancer Res 2019;38:232. [PMID: 31151472 DOI: 10.1186/s13046-019-1216-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
3 Lyu N, Kong Y, Pan T, Mu L, Sun X, Li S, Deng H, Lai J, Zhao M. Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. International Journal of Hyperthermia 2019;36:1002-10. [DOI: 10.1080/02656736.2019.1663279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Xu Q, Zhou L, Yang G, Meng F, Wan Y, Wang L, Zhang L. CircIL4R facilitates the tumorigenesis and inhibits ferroptosis in hepatocellular carcinoma by regulating the miR-541-3p/GPX4 axis. Cell Biol Int 2020;44:2344-56. [PMID: 32808701 DOI: 10.1002/cbin.11444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
5 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Nenu I, Breaban I, Pascalau S, Bora CN, Stefanescu H. The future is now: beyond first line systemic therapy in hepatocellular carcinoma. Transl Cancer Res 2019;8:S261-74. [PMID: 35117106 DOI: 10.21037/tcr.2018.11.23] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Lescure C, Estrade F, Pedrono M, Campillo-Gimenez B, Le Sourd S, Pracht M, Palard X, Bourien H, Muzellec L, Uguen T, Rolland Y, Garin E, Edeline J. ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3794. [PMID: 34359695 DOI: 10.3390/cancers13153794] [Reference Citation Analysis]
8 Berhane S, Fox R, García-Fiñana M, Cucchetti A, Johnson P. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer 2019;121:117-24. [PMID: 31182766 DOI: 10.1038/s41416-019-0488-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
9 Ebrahim HM, El-Rouby MN, Morsy ME, Said MM, Ezz MK. The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line. Asian Pac J Cancer Prev 2019;20:3369-76. [PMID: 31759361 DOI: 10.31557/APJCP.2019.20.11.3369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Reference Citation Analysis]
11 Adhoute X, Pénaranda G, Raoul JL, Bourlière M. Prognostication of HCC under sorafenib: Is it always possible? Liver Int 2020;40:1241-3. [PMID: 31705837 DOI: 10.1111/liv.14294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, Weinmann A, Marquardt JU, Vermehren J, Waidmann O. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. J Cancer Res Clin Oncol 2019;145:253-9. [DOI: 10.1007/s00432-018-2780-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
13 Hua X, Sanjiv K, Gad H, Pham T, Gokturk C, Rasti A, Zhao Z, He K, Feng M, Zang Y, Zhang J, Xia Q, Helleday T, Warpman Berglund U. Karonudib is a promising anticancer therapy in hepatocellular carcinoma. Ther Adv Med Oncol 2019;11:1758835919866960. [PMID: 31489034 DOI: 10.1177/1758835919866960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
14 Yao M, Sai W, Zheng W, Wang L, Dong Z, Yao D. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Curr Med Chem 2020;27:3290-301. [PMID: 31232234 DOI: 10.2174/0929867326666190624161158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Liao W, Huang J, Hutton D, Zhu G, Wu Q, Wen F, Bai L, Li Q. Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma. Liver Int 2019;39:2408-16. [DOI: 10.1111/liv.14257] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
16 Zhu Q, Luo M, Zhou C, Chen Z, Huang W, Huang J, Zhao S, Yu X. [Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2018;38:1476-84. [PMID: 30613017 DOI: 10.12122/j.issn.1673-4254.2018.12.13] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Noda S, Hira D, Osaki R, Fujimoto T, Iida H, Tanaka-mizuno S, Andoh A, Tani M, Ikeda Y, Morita S, Terada T. Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. Cancer Chemother Pharmacol 2020;86:129-39. [DOI: 10.1007/s00280-020-04105-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Wang Z, Cao B, Ji P, Yao F. Propofol inhibits tumor angiogenesis through targeting VEGF/VEGFR and mTOR/eIF4E signaling. Biochem Biophys Res Commun 2021;555:13-8. [PMID: 33812053 DOI: 10.1016/j.bbrc.2021.03.094] [Reference Citation Analysis]
19 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N. Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres. Biomed Res Int 2018;2018:1435302. [PMID: 30687734 DOI: 10.1155/2018/1435302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
21 Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
22 Song S, Bai M, Li X, Gong S, Yang W, Lei C, Tian H, Si M, Hao X, Guo T. Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35234564 DOI: 10.1080/14737159.2022.2049248] [Reference Citation Analysis]
23 Rudalska R, Harbig J, Snaebjornsson MT, Klotz S, Zwirner S, Taranets L, Heinzmann F, Kronenberger T, Forster M, Cui W, D’artista L, Einig E, Hinterleitner M, Schmitz W, Dylawerska A, Kang T, Poso A, Rosenfeldt MT, Malek NP, Bitzer M, Laufer S, Pichler BJ, Popov N, Schulze A, Zender L, Dauch D. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2021;2:201-17. [DOI: 10.1038/s43018-020-00168-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Srimathi U, Nagarajan V, Chandiramouli R. Investigation on graphdiyne nanosheet in adsorption of sorafenib and regorafenib drugs: A DFT approach. Journal of Molecular Liquids 2019;277:776-85. [DOI: 10.1016/j.molliq.2019.01.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 16.3] [Reference Citation Analysis]
25 Qin YJ, Lin TY, Lin XL, Liu Y, Zhao WT, Li XY, Lian M, Chen HW, Li YL, Zhang XL, Xiao D, Jia JS, Sun Y. Loss of PDK4 expression promotes proliferation, tumorigenicity, motility and invasion of hepatocellular carcinoma cells. J Cancer 2020;11:4397-405. [PMID: 32489458 DOI: 10.7150/jca.43459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Guy M, Pécheur EI. [Hepatic Hippo signaling inhibits protumoral microenvironment allowing to suppress hepatocellular carcinoma]. Med Sci (Paris) 2018;34:879-81. [PMID: 30451658 DOI: 10.1051/medsci/2018218] [Reference Citation Analysis]
27 Kong J, Zhang Q, Liang X, Sun W. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma. Open Med (Wars) 2020;15:702-8. [PMID: 33313412 DOI: 10.1515/med-2020-0129] [Reference Citation Analysis]
28 Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Pöschinger T, Kiessling F, Ries CH. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma. Hepatology 2019;70:1280-97. [PMID: 31002440 DOI: 10.1002/hep.30666] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 17.3] [Reference Citation Analysis]
29 Lin H, Zhang R, Wu W, Lei L. miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A. Oxid Med Cell Longev 2021;2021:9230435. [PMID: 34777698 DOI: 10.1155/2021/9230435] [Reference Citation Analysis]
30 Liu YT, Liu GQ, Huang JM. FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p-CCNG1 interaction network. Biosci Rep 2020:BSR20202054. [PMID: 33245102 DOI: 10.1042/BSR20202054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
32 Hong M, Li S, Ji W, Qi M, Ren G. Cocrystals of Lenvatinib with Sulfamerazine and Salicylic Acid: Crystal Structure, Equilibrium Solubility, Stability Study, and Anti-Hepatoma Activity. Crystal Growth & Design 2021;21:3714-27. [DOI: 10.1021/acs.cgd.1c00022] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Zhao S, Long M, Zhang X, Lei S, Dou W, Hu J, Du X, Liu L. The diagnostic value of the combination of Golgi protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: a diagnostic meta-analysis. Ann Transl Med 2020;8:536. [PMID: 32411759 DOI: 10.21037/atm.2020.02.89] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
34 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
35 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 286] [Article Influence: 89.3] [Reference Citation Analysis]
36 Zhang H, Zhong WL, Sun B, Yang G, Liu YR, Zhou BJ, Chen X, Jing XY, Huai LC, Liu N, Zhang ZY, Li MM, Han JX, Qiao KL, Meng J, Zhou HG, Chen S, Yang C, Sun T. Targeted Drug-Loaded Chemical Probe Staining Assay to Predict Therapy Response and Function as an Independent Pathological Marker. iScience 2019;21:549-61. [PMID: 31715498 DOI: 10.1016/j.isci.2019.10.050] [Reference Citation Analysis]
37 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Wang Q, Bin C, Xue Q, Gao Q, Huang A, Wang K, Tang N. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis 2021;12:426. [PMID: 33931597 DOI: 10.1038/s41419-021-03718-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
39 Wang Y, Wang Z, Jia F, Xu Q, Shu Z, Deng J, Li A, Yu M, Yu Z. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioactive Materials 2022;17:147-61. [DOI: 10.1016/j.bioactmat.2022.01.003] [Reference Citation Analysis]
40 Antunes F, Pereira GJS, Saito RF, Buri MV, Gagliardi M, Bincoletto C, Chammas R, Fimia GM, Piacentini M, Corazzari M, Smaili SS. Effective Synergy of Sorafenib and Nutrient Shortage in Inducing Melanoma Cell Death through Energy Stress. Cells 2020;9:E640. [PMID: 32155825 DOI: 10.3390/cells9030640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
42 Hou ZL, Han FY, Lou LL, Zhao WY, Huang XX, Yao GD, Song SJ. The nature compound dehydrocrenatidine exerts potent antihepatocellular carcinoma by destroying mitochondrial complexes in vitro and in vivo. Phytother Res 2022. [PMID: 35112410 DOI: 10.1002/ptr.7398] [Reference Citation Analysis]
43 Que J, Lin CH, Lin LC, Ho CH. Challenges of BCLC stage C hepatocellular carcinoma: Results of a single-institutional experience on stereotactic body radiation therapy. Medicine (Baltimore) 2020;99:e21561. [PMID: 32769898 DOI: 10.1097/MD.0000000000021561] [Reference Citation Analysis]
44 Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 2020;12:E1862. [PMID: 32664319 DOI: 10.3390/cancers12071862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
45 Huang X, Zhu S, Zhang K, Tan W, Chen Y, Shang C. High Expression of Long Non-Coding RNA TMCO1-AS1 is Associated With Poor Prognosis of Hepatocellular Carcinoma. Front Mol Biosci 2022;9:814058. [DOI: 10.3389/fmolb.2022.814058] [Reference Citation Analysis]
46 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
47 Meßner M, Schmitt S, Ardelt MA, Fröhlich T, Müller M, Pein H, Huber-Cantonati P, Ortler C, Koenig LM, Zobel L, Koeberle A, Arnold GJ, Rothenfußer S, Kiemer AK, Gerbes AL, Zischka H, Vollmar AM, Pachmayr J. Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma. FASEB J 2020;34:11860-82. [PMID: 32652772 DOI: 10.1096/fj.202001128R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ryoo BY, Cheng AL, Ren Z, Kim TY, Pan H, Rau KM, Choi HJ, Park JW, Kim JH, Yen CJ, Lim HY, Zhou D, Straub J, Scheele J, Berghoff K, Qin S. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:200-8. [PMID: 33972742 DOI: 10.1038/s41416-021-01380-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Liu S, Du Y, Ma H, Liang Q, Zhu X, Tian J. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. Cancer Lett 2019;453:74-83. [PMID: 30928380 DOI: 10.1016/j.canlet.2019.03.037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
50 Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Diesinger T, Lautwein A, Bergler S, Buckert D, Renz C, Dvorsky R, Buko V, Kirko S, Schneider E, Kuchenbauer F, Kumar M, Günes C, Genze F, Büchele B, Simmet T, Haslbeck M, Masur K, Barth T, Müller-Enoch D, Wirth T, Haehner T. A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:8854432. [PMID: 33604316 DOI: 10.1155/2021/8854432] [Reference Citation Analysis]
52 Umeh-Garcia M, Sweeney C. Cancer prevention through miRNAs: miR-206 prevents the initiation and progression of hepatocellular carcinoma by attenuating c-MET signaling and cell-cycle progression via cyclin D1 and CDK6. Noncoding RNA Investig 2018;2:37. [PMID: 31930188 DOI: 10.21037/ncri.2018.06.05] [Reference Citation Analysis]
53 D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin Pharmacol 2020;13:623-9. [PMID: 32394749 DOI: 10.1080/17512433.2020.1767591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
54 Kumar A, Kumar N, Sharma R, Bhargava G, Mahajan D. Direct Conversion of Carboxylic Acids to Various Nitrogen-Containing Compounds in the One-Pot Exploiting Curtius Rearrangement. J Org Chem 2019;84:11323-34. [PMID: 31393719 DOI: 10.1021/acs.joc.9b01697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
55 Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, Wu R, Lv Y, Dong J. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol 2019;75:105824. [PMID: 31437792 DOI: 10.1016/j.intimp.2019.105824] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
56 Hirai M, Kinugasa H, Nouso K, Yamamoto S, Terasawa H, Onishi Y, Oyama A, Adachi T, Wada N, Sakata M, Yasunaka T, Onishi H, Shiraha H, Takaki A, Okada H. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. J Gastroenterol Hepatol. 2020;. [PMID: 32830343 DOI: 10.1111/jgh.15227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Guillen A, Ressel L, Finotello R, German AJ, Freeman A, Blackwood L. Non-islet-cell tumour hypoglycaemia in a cat with hepatocellular carcinoma. JFMS Open Rep 2019;5:2055116919856129. [PMID: 31263567 DOI: 10.1177/2055116919856129] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Liu B, Bai C. Regulatory Mechanisms of Coicis Semen on Bionetwork of Liver Cancer Based on Network Pharmacology. Biomed Res Int 2020;2020:5860704. [PMID: 33294448 DOI: 10.1155/2020/5860704] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Guo Q, Yu DY, Yang ZF, Liu DY, Cao HQ, Liao XW. IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-κB signaling pathway. Dig Liver Dis 2020;52:573-81. [PMID: 31818638 DOI: 10.1016/j.dld.2019.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
60 Liao J, Zeng D, Li J, Hua Q, Xiao Z, He C, Mao K, Zhu L, Chu Y, Wen W, Zheng L, Wu Y. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int 2020;14:80-95. [DOI: 10.1007/s12072-019-10003-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
61 Setoguchi S, Watase D, Matsunaga K, Yamakawa H, Goto S, Terada K, Ohe K, Enjoji M, Karube Y, Takata J. Antitumor Effects and Delivery Profiles of Menahydroquinone-4 Prodrugs with Ionic or Nonionic Promoiety to Hepatocellular Carcinoma Cells. Molecules 2018;23:E1738. [PMID: 30013007 DOI: 10.3390/molecules23071738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Deeks ED. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. Target Oncol 2019;14:107-13. [PMID: 30767164 DOI: 10.1007/s11523-019-00622-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
63 Tian W, Li J, Wang Z, Zhang T, Han Y, Liu Y, Chu W, Liu Y, Yang B. HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation. Acta Pharm Sin B 2021;11:1592-606. [PMID: 34221870 DOI: 10.1016/j.apsb.2021.03.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
64 Catalano A, Iacopetta D, Sinicropi MS, Franchini C. Diarylureas as Antitumor Agents. Applied Sciences 2021;11:374. [DOI: 10.3390/app11010374] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
65 Aroua LM, Al-hakimi AN, Abdulghani MA, Alhag SK. Elaboration of novel urea bearing schiff bases as potent in vitro anticancer candidates with low in vivo acute oral toxicity. MGC 2022. [DOI: 10.3233/mgc-220019] [Reference Citation Analysis]
66 Zhang GC, Liu J, Yu XN, Deng Y, Sun Y, Liu TT, Dong L, Zhu CF, Shen XZ, Zhu JM, Weng SQ, Li Y. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma. Adv Healthc Mater 2020;9:e2000650. [PMID: 33000919 DOI: 10.1002/adhm.202000650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
67 Vauthier C. A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles. J Drug Target 2019;27:502-24. [PMID: 30889991 DOI: 10.1080/1061186X.2019.1588280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Reference Citation Analysis]
69 Wang XR, Wang S, Li WB, Xu KY, Qiao XP, Jing XL, Wang ZX, Yang CJ, Chen SW. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors. Eur J Med Chem 2021;213:113192. [PMID: 33493829 DOI: 10.1016/j.ejmech.2021.113192] [Reference Citation Analysis]
70 Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:12. [PMID: 30976715 DOI: 10.21037/tgh.2019.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
71 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
72 Ma YS, Liu JB, Wu TM, Fu D. New Therapeutic Options for Advanced Hepatocellular Carcinoma. Cancer Control 2020;27:1073274820945975. [PMID: 32799550 DOI: 10.1177/1073274820945975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
73 Duan X, Li H, Wang M, Ju S, Li F, Chen P, Lu H, Han X, Ren J. PSMC2/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma. Cell Death Discov 2021;7:217. [PMID: 34413286 DOI: 10.1038/s41420-021-00585-y] [Reference Citation Analysis]
74 Liu LM, Lin P, Yang H, Dang YW, Chen G. Gene profiling of HepG2 cells following nitidine chloride treatment: An investigation with microarray and Connectivity Mapping. Oncol Rep 2019;41:3244-56. [PMID: 30942464 DOI: 10.3892/or.2019.7091] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
75 Sirohi B, Shrikhande SV, Gaikwad V, Patel A, Patkar S, Goel M, Bal M, Sharma A, Shrimali RK, Bhatia V, Kulkarni S, Srivastava DN, Kaur T, Dhaliwal RS, Rath GK; Indian Council of Medical Research Guidelines Working Group. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res 2020;152:468-74. [PMID: 33707388 DOI: 10.4103/ijmr.IJMR_404_20] [Reference Citation Analysis]
76 Ma X, Wang J, Zhuang J, Ma X, Zheng N, Song Y, Xia W. P4HB modulates epithelial-mesenchymal transition and the β-catenin/Snail pathway influencing chemoresistance in liver cancer cells. Oncol Lett 2020;20:257-65. [PMID: 32565952 DOI: 10.3892/ol.2020.11569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
77 Paur J, Valler M, Sienel R, Taxauer K, Holzmann K, Marian B, Unterberger A, Mohr T, Berger W, Gvozdenovich A, Schimming J, Grusch M, Grasl-Kraupp B. Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma. Liver Int 2020;40:2279-90. [PMID: 32378800 DOI: 10.1111/liv.14505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
78 Zhang X, Liu T, Zhang Y, Liu F, Li H, Fang D, Wang C, Sun H, Xie S. Elucidation of the Differences in Cinobufotalin's Pharmacokinetics Between Normal and Diethylnitrosamine-Injured Rats: The Role of P-Glycoprotein. Front Pharmacol 2019;10:521. [PMID: 31156437 DOI: 10.3389/fphar.2019.00521] [Reference Citation Analysis]
79 Mansour GH, El-Magd MA, Mahfouz DH, Abdelhamid IA, Mohamed MF, Ibrahim NS, Hady A Abdel Wahab A, Elzayat EM. Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells. Bioorg Chem 2021;116:105329. [PMID: 34544028 DOI: 10.1016/j.bioorg.2021.105329] [Reference Citation Analysis]
80 Long L, Xiang H, Liu J, Zhang Z, Sun L. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells. Exp Mol Pathol. 2019;106:116-122. [PMID: 30615851 DOI: 10.1016/j.yexmp.2019.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
81 Feng S, Zhou J, Li Z, Appelman HD, Zhao L, Zhu J, Wang TD. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma. Colloids Surf B Biointerfaces 2019;184:110498. [PMID: 31536939 DOI: 10.1016/j.colsurfb.2019.110498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, Dalekos GN. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers (Basel) 2021;13:3510. [PMID: 34298722 DOI: 10.3390/cancers13143510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]